Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age > 69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

摘要

Reduced-intensity conditioning (RIC) allows for the use of allogeneic hematopoietic stem cell transplantation (HSCT) in older patients with acute myelogenous leukemia (AML). We compared outcomes between 713 patients age >= 70 years and 16,161 patients age 50 to 69 years who underwent HSCT between 2004 and 2014. A higher proportion of the older patients were male and had secondary AML, active disease, a peripheral blood stem cell graft, a matched unrelated donor, an RIC regimen, and a lower Karnofsky Performance Status (KPS) score (P = 70 years and 24% (95% CI, 25% to 32%) in those age 50 to 69 years (P = 70 years and 33% (95% CI, 31% to 34%) in those age = 70 years, a KPS score of >= 80% was associated with improved survival (hazard ratio, 1.53; 95% CI, 1.14 to 2.06: P = .003). In summary, patients age >= 70 years had worse outcomes, except for those with active AML. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.